Galapagos and Celera Genomics Sign Gene Function Analysis Agreement 
 

ROCKVILLE, M.D. and MECHELEN, Belgium, June 20, 2005 
Galapagos today announced that it has entered into a services 
agreement with Celera Genomics Group (NYSE:CRA), an Applera 
Corporation business. Under the agreement, Galapagos' services 
division Galadeno will provide technology and adenoviral reagents 
enabling Celera to analyze gene function in human cells and validate 
potential drug targets. Galadeno will receive payments related to 
its services and technology.Under the terms of the agreement, 
Galadeno will construct recombinant adenoviruses harboring genes 
selected by Celera. These custom-made viruses will be used to 
introduce the genes into various cell types to evaluate their 
function within biological pathways. 

 
 
 
 
"We are delighted that Celera has decided to take advantage of 
Galapagos' adenoviral technology. This service agreement will allow 
Celera to utilize Galapagos' technology platform to perform cellular 
assays and target validation studies in a very beneficial way," says 
Onno van de Stolpe, CEO of Galapagos. "Our adenoviral platforms have 
proven to deliver functionally validated drug targets for our 
partners, opening significant opportunities for continued 
collaboration. We are pleased that Celera has joined the growing 
number of companies that choose Galapagos technology to study gene 
function in human cells." 

About Celera Genomics and Applera Corporation Applera Corporation 
consists of two operating groups. The Celera Genomics Group is 
engaged principally in the discovery and development of targeted 
therapeutics for cancer, autoimmune and inflammatory diseases. 
Celera Genomics is leveraging its proteomic, bioinformatic, and 
genomic capabilities to identify and validate drug targets, and to 
discover and develop small molecule therapeutics. It is also seeking 
to advance therapeutic antibody and selected small molecule drug 
programs in collaboration with global technology and market leaders. 
The Applied Biosystems Group (NYSE:ABI) serves the life science 
industry and research community by developing and marketing 
instrument-based systems, consumables, software, and services. 
Customers use these tools to analyze nucleic acids (DNA and RNA), 
small molecules, and proteins to make scientific discoveries, 
develop new pharmaceuticals, and conduct standardized testing. 
Applied Biosystems is headquartered in Foster City, CA, and reported 
sales of $1.7 billion during fiscal 2004. Celera Diagnostics, a 
50/50 joint venture between Applied Biosystems and Celera Genomics, 
is focused on discovery, development, and commercialization of 
diagnostic products. Information about Applera Corporation, 
including reports and other information filed by the company with 
the Securities and Exchange Commission, is available at 
www.applera.com, or by telephoning +1.800.762.6923. Information 
about Celera Genomics is available at www.celera.com. 

About Galapagos 

Galapagos is a publicly traded, genomics-based drug discovery 
company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA) that 
has successfully discovered and validated novel targets in the bone 
and joint diseases - osteoarthritis, osteoporosis and rheumatoid 
arthritis, as well as in asthma and Alzheimer's disease. Proprietary 
targets and compounds resulting from these programs are used for 
Galapagos' internal drug discovery programs, combined with selected 
out-licensing and partnering of projects during development. 
Galadeno, Galapagos' services unit, provides reagents and functional 
screens to leading pharmaceutical, biotech and nutraceutical 
companies for rapid identification and validation of novel drug 
targets. Galapagos currently employs 69 people, including 17 PhDs, 
and occupies facilities in Mechelen, Belgium, and Leiden, The 
Netherlands. Partners include Bayer, Boehringer Ingelheim, Celgene, 
GlaxoSmithKline, Vertex and Wyeth. 




http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/";>Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/";>Arizona High Tech</a>
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
    http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
    [EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
    http://docs.yahoo.com/info/terms/
 


Reply via email to